Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06643208
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-10-13
Brief Title:
D-TACE-HAIC Combined With Envafolimab and Lenvatinib in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma a Prospective Single-arm Phase II Clinical Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Department of Hepatobiliary Pancreatic Surgery Fujian Provincial Hospital
Status:
RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a prospective single-arm multicenter phase II trial to evaluate the efficacy and safety of D-TACE-HAIC GEMOX protocol in combination with Envafolimab and Lenvatinib for unresectable intrahepatic cholangiocarcinoma
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None